Molecular Profiling of Liver Tumors: Classification and Clinical Translation for Decision Making

Pinyol, Roser; Nault, Jean–Charles; Quetglas, I.M.; Zucman‐Rossi, Jessica; Llovet, Josep M.

doi:10.1055/s-0034-1394137

Cited by 46 publications

(33 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A further confounding issue is represented by the great molecular and etiopathological heterogeneity of HCC, which contemplates a potential variability in precursor lesions. Indeed, several molecular classifications of HCC and driver genes have been proposed based on different molecular pathways and clinic-pathological features [2].…”

Section: Introductionmentioning

confidence: 99%

Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications

Sciarra

Tommaso

Nakano

et al. 2016

Journal of Hepatology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications

Sciarra

Tommaso

Nakano

et al. 2016

Journal of Hepatology

View full text Add to dashboard Cite

“…[28][29][30][31] As molecular- Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus signature assessments improve, these are also likely to contribute to better HCC patient selection. 32 Is there a role yet for neoadjuvant (downsizing) or adjuvant treatment? Using medical therapy, such as intrahepatic arterial chemoembolization or radioembolization, as a bridge to transplant has become common in many centers during the waiting period, which is often several months before a donor liver becomes available.…”

Section: Orthotopic Liver Transplant For Advanced Hepatocellular Carcmentioning

confidence: 99%

Untitled

Marino

Carr²

2017

Exp Clin Transplant

View full text Add to dashboard Cite

The use of orthotopic liver transplant for hepatocellular carcinoma was a major advance, pioneered by Thomas E. Starzl as a way to circumvent the limitations imposed on the liver surgeon by the presence of cirrhosis and liver failure. Patients with a few small tumors, whatever their degree of liver damage, may expect prolonged survival (70% at 5 years). Patients with more advanced tumors have high recurrence rates and more limited survival, possibly due to immune suppression or pretransplant understaging of their tumors. Another possibility is that patients with micrometastases have a longer survival time, during which the metastases eventually become evident. Recent advances include the identification of patients using levels of tumor markers to allow more careful patient selection with better outcomes. The con tributions of molecular signatures and the new, effective antiviral agents are possibly significant.

show abstract

“…As numerous cases of HCC are diagnosed at later stages when the prognosis is poor, the development of effective therapy for advanced and metastatic HCC is a high clinical priority (1,2). HCC is a heterogeneous disorder with a complex pattern of genetic alterations, and increasing our knowledge of the specific genes and signaling pathways involved in the pathogenesis of HCC is critical for identifying novel clinical tools for diagnosis, classification and targeted therapy of the disease (3,4).…”

Section: Introductionmentioning

confidence: 99%

“…The c-Myc oncoprotein is a helix-loop-helix transcription factor that regulates genes involved in promoting , XIAOLING ZHOU 1,3 , PAUL TONE 4 , MARIAN E. DURKIN 1,5 and NICHOLAS C. POPESCU tumorigenesis, cell proliferation and stem cell maintenance (12). Evidence accumulated in recent years clearly implicates the DLC1 and Myc genes in the pathogenesis of HCC in humans and in mouse models (13)(14)(15)(16)(17).…”

Section: Introductionmentioning

confidence: 99%

Cooperative antiproliferative effect of coordinated ectopic expression of DLC1 tumor suppressor protein and silencing of MYC oncogene expression in liver cancer cells: Therapeutic implications

Yang¹,

Zhou²,

Tone

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Human hepatocellular carcinoma (HCC) is one of the most common types of cancer and has a very poor prognosis; thus, the development of effective therapies for the treatment of advanced HCC is of high clinical priority. In the present study, the anti-oncogenic effect of combined knockdown of c-Myc expression and ectopic restoration of deleted in liver cancer 1 (DLC1) expression was investigated in human liver cancer cells. Expression of c-Myc in human HCC cells was knocked down by stable transfection with a Myc-specific short hairpin (sh) RNA vector. DLC1 expression in Huh7 cells was restored by adenovirus transduction, and the effects of DLC1 expression and c-Myc knockdown on Ras homolog gene family, member A (RhoA) levels, cell proliferation, soft agar colony formation and cell invasion were measured. Downregulation of c-Myc or re-expression of DLC1 led to a marked reduction in RhoA levels, which was associated with decreases in cell proliferation, soft agar colony formation and invasiveness; this inhibitory effect was augmented with a combination of DLC1 transduction and c-Myc suppression. To determine whether liver cell-specific delivery of DLC1 was able to enhance the inhibitory effect of c-Myc knockdown on tumor growth in vivo, DLC1 vector DNA complexed with galactosylated polyethylene glycol-linear polyethyleneimine was administered by tail vein injection to mice bearing subcutaneous xenografts of Huh7 cells transfected with shMyc or control shRNA. A cooperative inhibitory effect of DLC1 expression and c-Myc knockdown on the growth of Huh7-derived tumors was observed, suggesting that targeted liver cell delivery of DLC1 and c-Myc shRNA may serve as a possible gene therapy modality for the treatment of human HCC. IntroductionHuman hepatocellular carcinoma (HCC) is one of the most common and lethal types of cancer, and its incidence is increasing worldwide (1,2). As numerous cases of HCC are diagnosed at later stages when the prognosis is poor, the development of effective therapy for advanced and metastatic HCC is a high clinical priority (1,2). HCC is a heterogeneous disorder with a complex pattern of genetic alterations, and increasing our knowledge of the specific genes and signaling pathways involved in the pathogenesis of HCC is critical for identifying novel clinical tools for diagnosis, classification and targeted therapy of the disease (3,4).Despite the heterogeneity of genomic alterations in HCC, certain chromosomes or chromosomal sites are more frequently deleted or amplified, resulting in deregulation of crucial genes that may ultimately trigger malignant transformation of healthy hepatocytes (5). Chromosome 8 exhibits a highly recurrent pattern of DNA copy number loss on the short arm (8p21-p22) and gain on the long arm (8q22-q24) (5,6), and these genetic alterations are associated with HCC subclasses with a less favorable outcome (7). The 8p and 8q sites correspond with the loci of the tumor suppressor gene deleted in liver cancer 1 (DLC1) and the c-Myc proto-oncogene, respectively (8...

show abstract

Molecular Profiling of Liver Tumors: Classification and Clinical Translation for Decision Making

Cited by 46 publications

References 91 publications

Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications

Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications

Untitled

Cooperative antiproliferative effect of coordinated ectopic expression of DLC1 tumor suppressor protein and silencing of MYC oncogene expression in liver cancer cells: Therapeutic implications

Contact Info

Product

Resources

About